In its 2018 Annual Report to Shareholders, Henchman & Co. provided the following Statement of Cash Flows:

Years ended December 31 ($ in millions) Financing Activities Proceeds from issuance of long-term debt Proceeds from equity security units Borrowings under lines of credit Repayment of borrowings under lines of Credit Principal payments of long-term debt/lease agreements Proceeds from issuance of stock Dividends paid Other financing activities Net cash provided by (used in) financing activities Increase in cash and cash equivalents Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year 20181,4916901,173(1,306)(119)825(158)(64)2,532145319$4642017(175)(485)19(114)−(755)177142$319
-What method (direct or indirect) does Henchman & Co. use to present its Statement of Cash Flows? Explain how you can determine which method is used.
Urethral Obstruction
A blockage in the urethra, preventing the normal flow of urine from the bladder.
Renal Failure
A medical condition in which the kidneys lose their ability to function properly, resulting in the accumulation of toxins and waste in the body.
Bilirubin
A bile pigment formed by the breakdown of hemoglobin in the liver.
Liver Disease
A variety of conditions affecting the liver, including infections, genetic disorders, and issues stemming from substance abuse.